GCCL and Medicover Forge Strategic Alliance for Clinical Trial Enhancement GCCL and Medicover Integrated Clinical Services have announced a strategic partnership to boost multinational clinical trial operations, focusing on key global regions.

GCCL and Medicover Forge Strategic Alliance for Clinical Trial Enhancement #South_Korea #Clinical_Trials #Yongin #Medicover #GCCL

Medicover secures double-digit growth for 2025. Full-year revenue increased 13.7% to EUR 2,378.1 million, while the fourth quarter reached EUR 611.7 million with 10.6% organic growth. #Medicover #Healthcare

Raport: Chirurgia robotowa 2025 Modern Healthcare Institute opublikował raport na temat rozwoju chirurgii robotowej w Polsce w 2024 roku. Jak obliczono, koszt inkrementalny robotyki

Szpital #Medicover liderem w 🇵🇱 w operacjach z użyciem robota da Vinci – 2332 zabiegi od 2018 r. 🏆 W 2024 r. to 314 operacji, głównie prostatektomii. Jednym z głównych operatorów był dr n. med. Paweł Salwa, który w 2024 r. wykonał 219 zabiegów z użyciem robota da Vinci. 🤝 Raport 👉 mcov.me/sJGhF

@handelsbanken höjer riktkursen till 320 kr (260), rekommendation KÖP!

$MEDI #Medicover #finanstwitter #pratapengar #aktier #fintwit @avanzabank #avanza

Original post on 101010.pl

Dzwonil wlasnie jakis gosc z salonu optycznego #Medicover, z pytaniem jak mi sie sprawuja nowe okulary i jak idzie proces adaptacji.
Myslalem, ze byc moze pogadamy o ewentualnych modyfikacjach juz istniejacych okularow... ale nie, to byla po prostu zwykla rozmowa dosprzedazowa, zeby wepchnac mi […]

Medicover reports 17.1% revenue growth in Q2, margin improvement Investing.com -- Medicover ABon Thursday reported a 17.1% revenue growth in the second quarter of 2025, with organic growth of 13.9%, broadly in line with consensus expectations of 17.4%. The healthcare provider saw its adjusted EBITDA margin increase to 16.9% compared to 14.6% in the same period last year. This marks the first quarterly results under new CEO John Stubbington, who took over from Fredrik Rågmark on May 1. The Healthcare Services (NASDAQ:HCSG) segment led growth with a 17.5% revenue increase to €414 million, exceeding consensus estimates of approximately 16.8%. India returned to double-digit growth at 13.4% in constant exchange rates, though only 5% when reported. Organic growth in this segment reached 15.6%, including price increases of 8.7%. Diagnostic Services generated €189 million in revenue, growing 16% with organic growth of 9.9%. Laboratory test volume increased by 20.9% to 41.9 million tests, with acquisitions contributing 9.4% of this growth. The segment achieved an EBITDA margin of 17.7%. Acquisitions contributed €22.3 million to the company’s topline in the quarter, with €9.2 million coming from Healthcare Services and €13.1 million from Diagnostic Services. The newly acquired gyms were noted as margin supportive. Net debt to adjusted EBITDAaL ratio increased to 3.6x, exceeding the company’s 2025 leverage target of 3.5x due to acquisitions. Management expects this leverage to decrease in the second half of the year. The company’s Polish businesses continued to drive strong segment margins, along with improvements in the Romanian hospital business. However, new units in India and the new hospital in Bucharest remain a drag on margins, with a combined loss of €2.7 million in EBITDAaL for the quarter, an improvement from the €3.9 million loss in Q1. Medicover did not provide updated mid-term targets in its earnings release. The company’s stock currently trades at SEK257.50, with analysts maintaining a hold rating and a price target of SEK245.00, representing a 5% downside potential. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Medicover #RevenueGrowth #Healthcare #EarningsReport #Q2Results

Nowa placówka Medicover w Fabryka Park Katowice - Force News Medicover otwiera klinikę w rozbudowanym Fabryka Park Katowice. Nowe sklepy i usługi będą dostępny od przyszłego roku.

Katowice rozbudowują się!
Fabryka Park powiększa się o 2800 mkw., a kluczowym najemcą będzie Centrum Medyczne Medicover. To kolejny krok w rozwoju południowych dzielnic miasta.
#Katowice #Nieruchomości #Medicover #Inwestycje
⇣ forcenews.pl/fabryka-park...

Mieli pociąć nogę dziś, potną jutro. Bo skierowanie z października (!) jest nie takie, wystawili inne, ale w końcu będzie stary zabieg. Zgłupieć można w #Medicover 🤦‍♀️ wpadajcie na zrzutka.pl/bataliondonbas, szukamy kroplówki, mamy super aukcje!
Moja kolekcja-część trafi do Was🫡

Nieistniejące pacjentki, fałszywe recenzje. Tak Medicover promuje swoją porodówkę Ujawniamy, jak prywatny szpital od lat buduje swoją renomę na recenzjach od nieistniejących osób

Martwy Internet jest faktem. Obudźcie się!

#okoPress #Medicover

https://oko.press/fikcyjne-recenzje-szpitala-medicover

Medicover stock drops amid acquisition news Investing.com -- Shares of Medicover (STO:MCOV) fell by 2.7% today after the healthcare and diagnostic services provider announced the acquisition of Synlab’s businesses in various European countries. The deal, valued at €71.3 million, is set to expand Medicover’s footprint into three new markets but has raised concerns among investors. The acquisition, which will be consolidated from the second quarter of 2025, includes operations in Romania, Turkey, Cyprus, Slovenia, Croatia, and North Macedonia. These businesses generated revenue of €48 million in the fiscal year 2024. Medicover expects the deal to be accretive to earnings per share upon consolidation and projects to achieve more than 50% of the current profitability of the acquired entities within the next 12 months and over 100% in the subsequent 12 months. The company has outlined plans to generate synergies by centralizing advanced testing volumes and procurement. The acquisition is fully financed through Medicover’s existing committed loan facilities, which may have contributed to investor concerns about the financial impact and the integration of the new businesses. Analysts at Jefferies commented on the acquisition, noting potential benefits in the longer term: "Assuming a 5-10% EBITDA margin in FY24 and the margin expansion progresses as detailed, implies the acquisition could grow FY26 group Adj. EBITDA by <3.0%." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Medicover #StockMarket #Investing #Acquisitions #Healthcare

Medicover Reports Significant Revenue Growth in 2024 Year-End Financial Results Medicover announced substantial revenue growth in its 2024 year-end report, highlighting key financial metrics and strategic initiatives.

Medicover Reports Significant Revenue Growth in 2024 Year-End Financial Results #Sweden #healthcare #Stockholm #revenue_growth #Medicover

John Stubbington to Take Over as CEO of Medicover on May 1, 2025 Medicover AB has appointed John Stubbington as the new CEO effective May 1, 2025, succeeding Fredrik Rågmark after his remarkable tenure.

John Stubbington to Take Over as CEO of Medicover on May 1, 2025 #Sweden #Stockholm #CEO #Medicover #John_Stubbington

Medicover AB Considers Separate Listing for Indian Hospital Subsidiary to Boost Growth Medicover AB is exploring a potential separate listing for its Indian hospital subsidiary, aiming to enhance growth in India's healthcare sector.

Medicover AB Considers Separate Listing for Indian Hospital Subsidiary to Boost Growth #Sweden #India #Stockholm #Medicover #Hospital